Biohaven Ltd. (BHVN)
(Real Time Quote from BATS)
$55.30 USD
-1.72 (-3.02%)
Updated Mar 28, 2024 10:22 AM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Biohaven Ltd. (BHVN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$59.22 | $66.00 | $55.00 | 3.86% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Biohaven Ltd. comes to $59.22. The forecasts range from a low of $55.00 to a high of $66.00. The average price target represents an increase of 3.86% from the last closing price of $57.02.
Analyst Price Targets (9 )
Broker Rating
Biohaven Ltd. currently has an average brokerage recommendation (ABR) of 1.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.09 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90.91% and 9.09% of all recommendations. A month ago, Strong Buy made up 90.91%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 9 | 9 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.09 | 1.09 | 1.09 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/4/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
3/1/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
3/1/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
1/17/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
12/8/2023 | Robert W. Baird & Co. | Brian P Skorney | Not Available | Strong Buy |
10/8/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.09 |
ABR (Last week) | 1.09 |
# of Recs in ABR | 11 |
Average Target Price | $59.22 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | -1.50 |